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Sumlnary 
CD14 is a 55-kD protein found as a glycosylphosphatidylinositol (GPI)-anchored protein on 
the surface of monocytes, macrophages, and polymorphonuclear leukocytes, and as a soluble protein 
in the blood. Both forms of CD14 participate in the serum-dependent responses of cells to bacterial 
lipopolysaccharide (LPS). While CD14 has been described as a receptor for complexes of LPS 
with LPS-binding protein (LBP),  there has been no direct evidence showing whether a ternary 
complex of LPS,  LBP,  and CD14  is  formed,  or whether  CD14  binds  LPS  directly.  Using 
nondenaturing polyacrylamide gel electrophoresis (native PAGE),  we show that recombinant 
soluble CD14 (rsCD14)  binds LPS in the absence  of LBP or other proteins. Binding of LPS 
to CD14 is stable and of low stoichiometry (one or two molecules of LPS per rsCD14). Recombinant 
LBP (rLBP) does not form detectable ternary complexes with rsCD14 and LPS, but it does accelerate 
the  binding  of LPS  to  rsCD14,  rLBP  facilitates  the  interaction  of LPS  with  rsCD14  at 
substoichiometric concentrations, suggesting that LBP functions catalytically, as a lipid transfer 
protein. Complexes of LPS and rsCD14 formed in the absence of LBP or other serum proteins 
strongly stimulate integrin function on PMN and expression  of E-selectin  on endothelial cells, 
demonstrating that LBP is not necessary for CD14-dependent stimulation of cells. These results 
suggest that CD14 acts as a soluble and cell surface receptor for LPS, and that LBP may function 
primarily to accelerate the binding of LPS to CD14. 
R 
cent work has described several serum and cell surface 
proteins that are necessary for responses of leukocytes 
to low concentrations of bacterial LPS (endotoxin) (1). LPS- 
binding protein (LBP),I an acute phase reactant, binds LPS 
(2) and greatly enhances the sensitivity of cells to LPS (3). 
Normal serum and plasma also enhance responses  to LPS, 
and a multicomponent factor termed septin has been pro- 
posed to serve this function (4). LBP (5) and septin (4) each 
bind to LPS-coated particles and promote the interaction of 
these particles with CD14  (6,  7),  a glycosylphosphatidyl- 
inositol (GPI)-anchored protein of monocytes, macrophages, 
and PMN (8, 9,  10). CD14 is necessary for serum- or LBP- 
mediated responses  of cells to LPS, such as the production 
1 Abbreviations used in this paper: CHO, Chinese hamster ovary; ELPS, 
sheep erythrocytes  coated with LPS; ELPS-LBP, ELPS opsonized with 
LBP; GPI, glycosylphosphatidylinositol;  HAP, Dulbecco's PBS with 0.5 
U/ml aprotinin, 0.05% human  serum  albumin,  3 mM D-glucose;  HUVEC, 
human umbilical  vein  endothelial  cells; LBP,  LPS-binding  protein; NHP, 
normal human plasma; PD-EDTA, Dulbecco's PBS lacking Ca  2+  and 
Mg  2+  with 1 mM EDTA; Ra, strain R60; Re, strain R595; rLBP, re- 
combinant LBP; rsCD14, recombinant soluble CD14. 
of TNF by monocytes (6)  and an increase  in the adhesive 
properties of 132-integrins on PMN  (7). 
Cells that do not express CD14, such as endothelial cells, 
also respond to low concentrations of LPS in the presence 
of serum. We have shown that these responses require a soluble 
form of CD14 (sCD14)  (11), which is found at significant 
concentrations (2-6/zg/ml) in serum (12, 13). The involve- 
ment of soluble CD14 in inducing functional responses  of 
cells to LPS has recently been confirmed by other laborato- 
ries  (14-16). 
CD14 on macrophages binds erythrocytes coated with LPS 
and LBP, but not erythrocytes coated with LPS or LBP alone 
(5, 6). Moreover, CD14-dependent responses of monocytes 
to low concentrations of LPS occur in response  to LPS and 
LBP together, but not to either LBP or LPS alone (3). CD14 
has thus been known as a receptor for LPS-LBP complexes. 
Here we provide direct evidence that rsCD14 binds LPS in 
the absence of other proteins, and that rsCD14-LPS com- 
plexes initiate physiologic responses from both CD14-express- 
ing and CD14-negative cells. We further show that rLBP 
increases the rate of LPS binding to rsCD14 but is not neces- 
sary for inducing functional responses  of cells. 
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Reagents.  LPS from Salmonella minnesota strain  R595 (Re), S. 
minnesota strain  R60 (Ra),  and from Escherichia coli 0111:B4 were 
purchased  from  List  Biological  Laboratories  (Campbell,  CA). 
3H-labeled LPS from E. coli K12 strain LCD25 (17) was a generous 
gift of Dr. Robert Munford (University of Texas Southwestern Med- 
ical Center, Dallas, TX). Synthetic lipid IVa (LA-14-PP) was pur- 
chased from ICN Biomedicals, Inc. (Costa Mesa, CA). Anti-CD14 
mAbs 3C10 (18), 60b (19), and 26ic (19) were purified from ascites 
fluid by chromatography on Protein G. Anti-E-selectin mAb BB11 
(20) was a generous gift of Dr. R. Lobb (Biogen Inc., Cambridge, 
MA). Fresh frozen normal human plasma (NHP) was supplied by 
the New York Blood Center (New York). 
Stable Expression ofrsCD14.  An expression plasmid containing 
the full-length cDNA for human CD14 (9) was used as a template 
in a PCR to generate a fragment that lacks codons for eight COOH- 
terminal amino acids (rsCD14).  The oligonucleotide pair (5' GTC 
CCT CTA GAC CAC CAT GGA GCG CGC GTC CTG C  + 
5' TCC AGG TCG ACT TAC AGC ACC AGG GTT CCC GA) 
used  in the PCR was designed to introduce an XbaI site  and a 
perfect Kozak sequence (21) preceding the rsCD14 initiator codon, 
and to introduce a SalI site following the stop codon introduced 
after amino acid 367 in CD14. DNA sequence analysis verified the 
PCR-generated changes as well as the integrity of the remainder 
of the  CD14  cDNA.  The  rsCD14  gene was  then  cloned  as  a 
XbaI-SalI fragment into the mammalian expression vector pDSRcr 
(European Patent Application A20398753) that was modified  to 
include unique XbaI and SalI restriction  sites, pDSRa2 allows high- 
level expression of recombinant proteins in Chinese hamster ovary 
(CHO) transfectants.  The rsCD14 expression  vector was used to 
transfect  a  CHO  cell  line  deficient  in  dihydrofolate  reductase 
(CHO D)  (22) by selecting  for transfectants  in medium lacking 
hypoxanthine and thymidine (23). An RNase protection assay (24) 
was used to screen for transfectants  that had high levels ofrsCD14- 
specific mRNA. A single clone was grown without serum as de- 
scribed (23) to generate conditioned medium containing rsCD14. 
Purification ofrsCD14,  rsCD14 was purified by immunoaffanity 
chromatography on a column of 3C10 mAb coupled to Sepharose 
4B. Serum-free  conditioned medium was passed over the column 
which was preequilibrated  with PBS. Protein was monitored by 
following absorbance at 280 nm. After the medium was applied, 
the column was washed with PBS until the A280 reached baseline 
absorbance.  The protein was then eluted with 0.1 M glycine-HC1, 
pH 2.5, into collection tubes containing 1 M phosphate, pH 8.0. 
Protein bands were detected by silver staining a 10%  SDS-PAGE 
gel.  rsCD14-containing fractions were then pooled and concen- 
trated in a Centriprep-10 (Amicon, Beverly, MA). NH2-terminal 
sequencing on a G1000a sequencer (Hewlett-Packard Co., Palo Alto, 
CA) confirmed that  the isolated  protein was rsCD14.  Based on 
a visual inspection of a silver-stained  gel,  purity was estimated to 
be greater than 95%. Endotoxin levels were determined to be <0.4 
ng LPS/mg rsCD14 using the Limulus amebocyte lysate assay (As- 
sociates  of Cape Cod,  Inc., Woods Hole,  MA). 
Stable Expression of  rLBP in a CHO D Cell Line.  PCR was per- 
formed on Human Quick-Clone liver cDNA (Clontech, Palo Alto, 
CA) to generate two overlapping fragments that span  the entire 
LBP cDNA sequence (3) (Accession No. 35533). The oligonucleo- 
tide pairs (5' GTC CCT CTA GAC CAC CAT GGG GGC CTT 
GGC AAG A  +  5' GAG TCA GGC GGT ATC ATG and 5' TCC 
CGG TCG ACT TAA ACT CTC ATG TAT TGG AC +  5' GTC 
TTC AAC ACG GCC AGC) used in the PCR were designed  to 
introduce an XbaI site and a perfect Kozak sequence preceding the 
LBP initiator codon, and to introduce a SalI site after  the natural 
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stop codon in LBP. The two PCR fragments were then ligated 
together to form full-length LBP by ligating an XbaI-EcoRV frag- 
ment from the first PCR reaction to an EcoRV-SalI fragment from 
the second PCR reaction in pSL1180 (Pharmacia  Fine Chemicals, 
Piscataway, NJ). The LBP cDNA was sequenced in its entirety and 
the deduced amino acid sequence was found to match exactly the 
revised LBP amino acid sequence (25). The rLBP cDNA was then 
cloned as an XbaI-SalI fragment in the modified pDSRcr  A single 
transfectant  was  propagated as described  for rsCD14. 
Purification ofrLBP,  rLBP-containing conditioned medium was 
concentrated  17-fold  using  an  $10Y30  spiral  wound  cartridge 
(Amicon). Concentrated medium was diluted 1:3 with 50 mM so- 
dium phosphate,  pH 7.3, 2 mM EDTA, 40 mM NaC1, then ap- 
plied  to a Mono S column (Pharmacia  Fine Chemicals)  that had 
been  equilibrated  with  the  same buffer.  The column was  then 
washed with equilibration buffer to baseline absorbance, and bound 
proteins  were eluted with a 120-ml gradient of 40-300 mM NaC1 
in 50 mM phosphate,  pH 7.3,  2 mM EDTA.  rLBP was detected 
by silver staining a 10%  SDS-PAGE gel loaded with eluted  pro- 
teins. NH2-terminal  sequencing confirmed  an isolated 60-kD band 
as rLBP. Purity was estimated at greater than 95% and the Limulus 
amebocyte lysate assay indicated that endotoxin levels were less than 
0.9 ng LPS/mg rLBP. Purified  rLBP exhibited  the predicted  bio- 
logical activities. It enabled responses of PMN to low doses of LPS 
but did not by itself stimulate  cells (Fig.  1). rLBP also opsonized 
LPS-coated erythrocytes for recognition by CD14 on macrophages 
(Fig.  2). 
Electrophoresis.  Proteins  and sonicated LPS were diluted in PD- 
EDTA  (Dulbecco's  PBS  lacking  Ca  2+  and  Mg  2+,  with  1  mM 
EDTA) and incubated at 37~  for various times, and bromophenol 
blue and glycerol were added before  electrophoresis.  Tris-glycine 
polyacrylamide gradient gels  (continuous buffer,  pH 8.6;  1.0 or 
1.5 mm thick) were purchased  from Novex (San Diego, CA) and 
electrophoresed  at 100-150 V for 2 h in a running buffer containing 
192 mM glycine,  24 mM Tris, pH 8.3, without detergents.  Am- 
moniacal silver staining was performed according to published proce- 
dures (26). Gels containing 3H-LPS were fixed in 30% methanol, 
Figure  1.  .Adhesion  of PMN to fibrinogen  in response  to LPS and plasma 
or LPS and LBP. The indicated concentrations of LPS (Re, R595) alone 
(ll), with 2% NHP (O),  or with  1 ~g/ml rLBP (A) were incubated 
with PMN and adhesion to fibrinogen-coated  wells was measured as de- 
scribed in Materials and Methods. Mean values for triplicate determina- 
tions are shown. Bars, PMN were pretreated with 10/~g/ml of the indi- 
cated anti-CD14 mAb, then washed and incubated with 100 ng/ml LPS 






Figure  2.  rsCD14  enables HUVEC to express E-selectin in response 
to LPS. HUVEC were incubated for 4 h with the indicated concentra- 
tions of LPS in the presence of medium alone (I), 0.5 % CD14-depleted 
human serum (O), 0.5% CD14-depleted serum reconstituted with 0.07 
/zg/ml rsCD14 (A), or 0.07/~g/ml rsCD14 (A). Expression  of E-selectin 
was then measured as described in Materials and Methods. Results are 
expressed in arbitrary fluorescence  units and are representative  of six sepa- 
rate experiments. 
10% acetic acid for 1 h, soaked in EN3HANCE (Dupont, Boston, 
MA), washed in dH20, dried, and exposed to Kodak XAR, film 
for 2-10 d. 
Human  Umbilical Vein Endothelial Cells (HUVEC).  HUVEC 
were cultured, stimulated with LPS, and assayed for expression of 
E-selectin (ELAM-1) exactly as described (11). Briefly, monolayers 
of confluent cells were exposed to dilutions of serum or CD14- 
depleted serum and LPS for 4 h at 37~  The monolayers were 
washed, and antigen expression was measured using the anti-E- 
selectin  monoclonal  antibody  BB11, an  alkaline  phosphatase- 
conjugated second antibody, a fluorogenic substrate, and a Cytofluor 
apparatus  (Millipore Corp.,  Bedford, MA).  Human  serum was 
depleted of sCD14 by passage over a column of immobilized anti- 
CD14 mAb 60b as previously described (11). 
Binding of LPS-coated Erythrocytes to MacroFhages.  The binding 
of opsonized sheep erythrocytes to monocyte-derived macrophages 
was performed as described (5) with modifications. LPS-coated sheep 
erythrocytes (ELPS) were formed by incubating sonicated LPS (Re, 
R595) with sheep erythrocytes at a dose of 10/~g LPS/108 sheep 
erythrocytes. After 1 h at 37~  the cells were washed extensively 
and resuspended in 5 mM veronal buffer, pH 7.5, with 150 mM 
NaCI, 0.1% gelatin, 1 mM EDTA (EDTA-GVB2-). To opsonize 
the ELPS for binding to cell surface CD14, ELPS were incubated 
with rLBP diluted in PD-EDTA, at a dose of 0.5 /zg rLBP/10  s 
ELPS, for 10 rain at 37~  The LBP-opsonized ELPS (ELPS-LBP) 
were then washed and resuspended in EDTA-GVB  2- . Binding to 
macrophages was measured by adding 5  x  105 ELPS-LBP to a 
monolayer of macrophages formed on a 60-well Terasaki plate and 
incubating for 15 min at room temperature. Unbound ELPS-LBP 
were removed by inverting the plate for 10 min and gently washing 
the monolayer. Binding of ELPS-LBP to macrophages was evalu- 
ated by phase contrast microscopy and expressed as the attachment 
index, the number of ELPS-LBP bound per 100 macrophages. 
Adhesion of  PMN to Fibrinogen.  We have previously shown that 
PMN respond to LPS with a dramatic rise in the ability of the 
leukocyte integrin  CR3  (Mac-l,  Otm~2, CDllb/CD18)  to bind 
C3bi-coated erythrocytes (7). CR3 recognizes not only C3bi but 
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also fibrinogen (27, 28), and thus the activation of CR3 on PMN 
can be measured using surface-bound fibrinogen rather than surface- 
bound C3bi as the ligand (Van Kessel, K. P. M., and S. D. Wright, 
manuscript in preparation). We have measured the effect of LPS 
on PMN by observing adhesion of PMN to fibrinogen-coated sur- 
faces. Briefly, PMN were purified from freshly drawn blood from 
normal human donors using Neutrophil Isolation Medium (Cardinal 
Associates, Santa Fe, NM), according to the manufacturer's  instruc- 
tions. Suspensions  of 5  x  106 PMN/ml in HAP (Dulbecco's PBS 
containing 0.5 U/ml of aprotinin, 0.05% (wt/vol) human serum 
albumin, and 3 mM o-glucose) were fluorescently labeled with 5 
/xM 5-(and 6-)carboxyfluorescein diacetate,  succinimidyl ester for 
20 min at room temperature. The PMN were then pelleted and 
resuspended  at  2.5  x  106/ml  in  HAP.  72-well  Terasaki  plates 
(P,  obbins Scientific  Corp.,  Sunnyvale,  CA) were coated with  1 
mg/ml human fibrinogen in PBS for I h at room temperature, and 
washed three times with PBS. 5/xl of PMN were added to each 
well, followed by 5/zl of protein/LPS samples diluted in PD-EDTA. 
After a 20-min incubation at 37~  fluorescence was measured in 
a  Cytofluor  apparatus  (Millipore  Corp.),  plates  were  washed 
vigorously in PBS to remove unbound PMN, and fluorescence was 
measured again. Percent adhesion was calculated as postwash fluores- 
cence divided by prewash fluorescence for each well. Values given 
in figures are mean values for triplicate determinations. 
PMN bind fibrinogen-coated wells in response to LPS and LBP 
or LPS and plasma  (Fig.  1). The stimulation of binding by LPS 
requires CD14 since binding is blocked by 60b and 3C10,  anti- 
CD14  mAbs  that  have  previously been  shown  to  block  LPS- 
dependent responses of CD14-bearing ceUs (6). A control anti-CD14 
monodonal antibody, 26ic, which does not block responses of mono- 
cytes or PMN or LPS (6),  did not block responses  in this assay 
(Fig.  1, bars). Binding of the stimulated cells to the fibrinogen- 
coated surface  is  mediated by leukocyte integrins  (Van Kessel, 
K. P. M.,  and S. D.  Wright,  manuscript in preparation). 
Results 
rsCD14 Mediates Expression of  E-Selectin by HUVEC in Re- 
sponse to LPS.  We produced a recombinant soluble CD14 
(rsCD14) that lacks the eight COOH-terminal amino acids. 
Several observations indicate that rsCD14 is correctly folded 
and biologically active. Gel filtration of rsCD14 on Superose 
12  showed a  single peak with  a calculated M~ of '~45,000 
(not shown), indicating that the protein is not aggregated. 
sCD14  is known  to be essential for responses of HUVEC 
to LPS since depletion of sCD14 from plasma prevents in- 
duction of E-selectin in response to LPS (II). We found that 
rsCD14 reconstituted the ability of CD14-depleted serum to 
enable induction of E-selectin (Fig. 2). To reconstitute this 
function, rsCD14  must interact with LPS, with cells, and, 
we presume, with opsonins in serum; we thus conclude that 
all these properties  are intact  in our recombinant  protein. 
Addition of rsCD14 with LPS caused increased expression 
of E-selectin on HUVEC even in the absence of LBP or serum 
proteins (Fig. 2). This result confirms our previous finding 
that sCD14 isolated from serum enables an LPS-dependent 
but serum-independent response from three types of cells that 
do not bear CD14:  HUVEC,  bovine endothelial cells, and 
the astrocytoma cell line U373 (11). It is also consistent with 
the recent findings of several laboratories (14-16, Sundan, A., 
S. D.  Wright,  and T.  Espevik,  manuscript  in preparation) that sCD14 from serum, urine, and transfected cells can en- 
able responses of cells to LPS in the apparent absence of serum 
or LBP.  In our previous study (11)  we speculated that  this 
apparent lack of a need for serum opsonins could be explained 
if the sCD14 from serum were contaminated with serum op- 
sonins. This explanation is unlikely for the sCD14 employed 
here, since rsCD14 was isolated from serum-free conditioned 
medium.  Moreover, rsCD14 is unlikely to be physically as- 
sociated with a protein of significant mass, since monomeric 
rsCD14 from a gel filtration column was capable of stimulating 
HUVEC in an LPS-dependent and serum-independent fashion 
(not shown). These results suggest that rsCD14 may interact 
with LPS directly, without the intercession of opsonic pro- 
teins  such  as  LBP or  septin. 
rsCD14 Prevents  Opsonization of  ELPS  for Recognition by Mac- 
rophages.  Membrane-bound  CD14  (mCD14)  is known  to 
mediate binding of LBP-opsonized ELPS (ELPS-LBP) to mac- 
rophages (6). Addition of rsCD14 with rLBP during opso- 
nization  of ELPS  inhibited  the  subsequent  binding  of the 
erythrocytes to macrophages (Fig. 3). This finding suggests 
that rsCD14 can bind to LPS-LBP complexes on the surface 
of the erythrocyte, blocking interaction with mCD14. How- 
ever, rsCD14 was also able to prevent binding of ELPS-LBP 
to macrophages when it was incubated with ELPS in a step 
preceding opsonization with  rLBP (Fig.  3).  This observa- 
tion suggests  that rsCDl4  is able to interact directly with 
LPS in the erythrocyte membrane, preventing subsequent op- 
sonization of ELPS by rLBP. This observation, and the ability 
of rsCD14  to mediate  functional responses  of HUVEC  to 
LPS, led us to investigate whether rsCD14 binds LPS directly. 
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Figure 3.  rsCD14  competes  with cell surface CD14 for binding  of 
ELPS-LBP. ELPS were opsonized with 0.5/~g/ml rLBP in the presence 
of  various concentrations of rsCD14 ( -  ￿9 -), or pretreated with rsCD14 
for 10 min and then washed before opsonization with 0.5/~g/ml  rLBP 
(-[~--). Attachment of erythrocytes to macrophages was measured as 
described in Materials and Methods. Data are expressed  as the attachment 
index, the number of erythrocytes bound per 100 macrophages, and are 
mean values (_+ SD) for three wells. In this experiment, ELPS in the ab- 
sence of LBP gave an attachment index of 5. Substitution of HSA (up 
to I mg/ml) for rsCD14 in either the preincubation or opsonization step 
caused no inhibition of the binding of ELPS-LBP to macrophages. 
sCDI4-LPS  Complexes Can  Be  Detected Using Native 
PAGE,  We used native PAGE to examine the binding  of 
rsCD14  to LPS in  solution.  When  rsCD14  was  incubated 
with  LPS  for  30  min  at  37~  before electrophoresis,  the 
rsCD14  band  exhibited increased electrophoretic mobility. 
Three distinct forms of rsCD14 could be observed: Form 1, 
seen when rsCD14 was incubated without LPS (Fig. 4, lane 
1); Form 2, of intermediate mobility (Fig. 4, lane 3), resulting 
from incubation of rsCD14 with 50 #g/ml LPS; and Form 
3, of highest mobility (Fig. 4, lane 4), seen only after incuba- 
tion of rsCD14 with very high concentrations (9500 #g/ml) 
of LPS. At lower LPS concentrations (5 ~g/ml), both Forms 
1  and  2  were present  (Fig.  4,  lane 2). 
Several observations suggest that the shift in electrophoretic 
mobility described above is caused by stable binding of LPS 
to rsCD14.  (a) The shift in mobility is not an artifact caused 
by high concentrations of LPS in native PAGE, since several 
unrelated proteins showed no change in electrophoretic mo- 
bility in native PAGE upon incubation with  LPS (Fig.  5). 
(b) The proportion ofrsCD14 migrating as Form 2 increased 
upon longer incubation with LPS before electrophoresis (see 
Fig. 11), suggesting that the phenomenon under study occurs 
Figure 4.  Incubation of LPS 
with rsCD14 induces  a shift  in the 
electrophoretic  mobility of  CD14 
in  native PAGE. rsCD14 (30 
#g/ml) was incubated  for 30 min 
at 37~  with different  concentra- 
tions of LPS (Re), and run in a 
4-20% native  polyacrylamide  gel, 
which was subsequently stained 
with silver. Lane I, no LPS; lane 
2, 5  #g/ml  LPS; lane  3, 50 #g/ml 
LPS; lane 4, 500 #g/ml LPS. Po- 
sitions of  protein standards are in- 
dicated in kilodahons. 
Figure 5.  LPS does not affect 
the mobility of proteins  unrelated 
to CD14. The indicated proteins 
were incubated  at 30/xg/ml alone 
or with 10 or 100/zg/ml  LPS (Re) 
for 2 h at 37~  and run  in a 
4-12% native  polyacrylamide  gel, 
which was subsequently stained 
with silver. Lanes  a, no LPS; lanes 
b,  10 /zg/ml LPS; lanes c,  100 
#g/ml LPS. 
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resis.  (c) There was  no change in  the mobility of rsCD14 
in SDS-PAGE after incubation with LPS (not shown). This 
result rules out the possibility that incubation with LPS caused 
proteolytic degradation of rsCD14, resulting in increased elec- 
trophoretic mobility.  (d)  Most  importantly, incubation of 
rsCD14 with radioactively labeled LPS yielded a radioactive 
band in native PAGE at  the same position as rsCD14-LPS 
complexes seen with  silver  staining  (Fig.  6). 
We used LPS labeled to high specific activity with tritium 
(3H-LPS)  (17)  to  confirm  that  CD14-LPS  complexes are 
stable  in  native PAGE.  3H-LPS ran  with  a  high  apparent 
molecular weight in native PAGE, presumably in micellar 
form (Fig. 6, lane 2). When incubated with rsCD14 before 
electrophoresis, a portion of the 3H-LPS migrated in a com- 
plex with rsCD14, at the same position as rsCD14-LPS com- 
plexes seen in silver-stained gels (Fig.  6, lane 3). Incubation 
with as much as 100/~g/ml human serum albumin did not 
affect the mobility of 3H-LPS (not shown), suggesting that 
formation of a complex with LPS that is stable in native PAGE 
may be  specific  for  CD14.  While  we  have  not  observed 
3H-LPS comigrating with rLBP in native PAGE, rLBP does 
increase the mobility of 3H-LPS (see Fig.  8, lanes  1 and 5), 
suggesting a rapidly reversible interaction of LBP with LPS. 
To further explore the specificity of the interaction of LPS 
with rsCD14, binding was measured in the presence of com- 
peting doses of unlabeled endotoxins. Unlabeled LPS com- 
pletely eliminated the 3H-LPS-rsCD14 band on native gels 
(Fig. 6). Competition was seen with rough and smooth forms 
of LPS,  as well as with lipid IVa,  a synthetic precursor of 
LPS. These forms of LPS also caused a shift in the mobility 
ofrsCD14 in native PAGE, but the shift was less pronounced 
than that  caused by Re LPS (data not  shown). 
LBP Accelerates Binding of LPS to rsCD14 without Forming 
Stable Complexes with rsCDI  4 and LPS.  To determine whether 
Figure 6.  3H-LPS  comigrates with rsCD14 in native PAGE. 3H-LPS 
(1 /~g/ml) was incubated with or without rsCD14 (50/~g/ml) for 4 h 
at 37~  then run in an 8-16% native  polyacrylamide  gel. Fluorography 
was performed  as described  in Materials and Methods. Lane I, 14C-mo- 
lecular mass markers (Sigma Chemical  Co.), indicated  in kilodaltons;  lane 
2, 3H-LPS; lane 3, 3H-LPS  and rsCD14. Lanes 4-15 show competitive 
inhibition of the binding of 3H-LPS to rsCD14 with unlabeled endo- 
toxins. Unlabeled LPS (lane a, 5/~g/ml; lane b, 50 #g/ml; lane c, 500 
/~g/ml) was added with 3H-LPS to rsCD14 and incubated as in lane 3. 
Lanes 4-6, lipid  IVa; lanes 7-9, Re LPS (R595); lanes I0-12, Ra LPS (R60); 
lanes 13-I5, smooth LPS (Ol11:B4). 
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Figure  7.  rLBP  does  not form 
stable complexes  with rsCD14 and 
LPS. rsCD14 and rLBP  were in- 
cubated  with or without  LPS (Re) 
at the indicated  concentrations  for 
30 min  at  37~  and run in a 
4-20% native  polyacrylamide  gel, 
which was subsequently  stained 
with silver. Lane 1, rsCD14 (30 
/~g/ml) and  rLBP (30 /~g/ml); 
lanes a, rsCD14 (30 #g/ml) and 
rLBP (3 #g/ml); lanes b, rsCD14 
(30 #g/ml) and rLBP  (10 #g/ml); 
lanes c, rsCD14 (30 gtg/ml) and 
rLBP  (30/zg/ml); lanes  d, rsCD14 
(10/~g/ml) and rLBP (30 #g/ml). The rsCD14 migrates as Form 1 in 
lane 1, as Form 2 in lanes 2-8, and as form 3 in lane 9. 
LBP forms a stable  complex with LPS and CD14,  we in- 
cubated various concentrations of rLBP and rsCD14 with 
LPS and analyzed the samples  by native PAGE.  There was 
no decrease in staining of monomeric rsCD14 or rLBP, and 
no proteins were seen at positions predicted for LBP-CD14 
dimers or higher order aggregates (Fig.  7).  Thus, we were 
not able to detect complexes of rLBP with rsCD14 and LPS. 
However, rLBP had a profound effect on the binding of LPS 
to  rsCD14.  During  30-min  incubations  of 3H-LPS with 
rsCD14,  the amount of rsCD14-LPS complex formed at a 
given concentration of rsCD14 was greatly increased  in the 
presence of rLBP (Fig. 8). These results show that rLBP pro- 
motes the interaction of LPS and rsCD14 without forming 
part of the final complex, and suggests that rLBP increases 
the rate of binding of LPS to CD14. 
To confirm the kinetic effect of rLBP on interactions of 
rsCD14 with LPS, we examined the time course of the binding 
of 3H-LPS to a molar excess of rsCD14. The rate of binding 
of 3H-LPS to rsCD14 was dramatically increased by rLBP 
at a molar concentration ~150-fold lower than the concen- 
tration of 3H-LPS (Fig.  9). rLBP did not appear to affect the 
affinity of 3H-LPS for rsCD14, because a quantitative shift 
of 3H-LPS from  its  aggregated  form  to  complexes with 
rsCD14 was seen in the presence or absence of rLBP. How- 
ever, the time required for complete binding to rsCD14 was 
reduced from several hours to less than 30 min by the pres- 
ence of rLBP. After 30 rain of incubation, less than half of 
the 3H-LPS was bound to rsCD14 in the absence  of rLBP 
(Fig.  9, lane 4), whereas in the presence of rLBP, virtually 
all of the LPS appeared to be bound to rsCD14 (Fig.  9, lane 
Figure  8.  rLBP  increases the 
amount of  LPS bound  to rsCD14. 
3H-LPS (3 ?tg/ml) was incubated 
with the indicated  concentrations 
of rsCD14 and rLBP  for 30 rain 
at 37~  run in a 4-20% native 
polyacrylamide  gel, and detected 
by flnorography. Figure 9.  rLBP  accelerates  the 
binding  of  LPS  to  rsCD14. 
3H-LPS (1/~g/ml) was incubated 
with rsCD14 (50/zg/ml) for the 
indicated times with or without 
rLBP (100 ng/ml) at 37~  run 
in a 4-12% native  polyacrylamide 
gel, and detected  by fluorography. 
Lane 1, 14C-labeled  protein stan- 
dards, indicated in  kilodaltons; 
lanes 2-7,  time course without 
LBP; lanes 8-13, time  course  with 
100 ng/ml rLBP. 
I0).  Since 3H-LPS was present in a large molar excess of the 
concentration of rLBP, this result suggests that rLBP did not 
form a stoichiometric complex with 3H-LPS and rsCD14, 
but rather acted substoichiometrically to accelerate binding 
of 3H-LPS and rsCD14. 
LBP Enables Stoichiometric Binding of LPS to CD14 at Sub- 
stoichiometric Concentrations.  To confirm that rLBP was effec- 
tive in substoichiometric concentrations, we used silver staining 
of native PAGE to examine the proportion of rsCD14 that 
binds to LPS (Re) in the presence or absence of rLBP (Fig. 
10). During a 30-min incubation, the presence of rLBP in- 
creased the amount of rsCD14 exhibiting increased mobility 
at a given LPS concentration. When approximately equimolar 
concentrations of rsCD14 and LPS were used (Fig.  10, lanes 
4 and 8), the presence of 20-fold less rLBP resulted in half 
of the rsCD14 binding to LPS, as measured by densitometric 
scanning (not shown). A single molecule of rLBP thus caused 
the transfer of at least 10 molecules of LPS to rsCD14 in 30 
rain, confirming that LBP is able to accelerate binding at sub- 
stoichiometric concentrations. These results indicate that LBP 
facilitates binding of LPS to rsCD14 without being consumed, 
and we thus propose that LBP acts as a classical catalyst to 
transfer LPS to CD14. A further consequence of this model 
is that LBP is not directly involved in the stimulation of LPS- 
responsive cells  (see below). 
An estimate of the stoichiometry of the binding of LPS 
and rsCD14 can be made based on the amount of rsCD14 
complexed with a given concentration of  LPS. As noted above, 
equimolar concentrations of LPS and rsCD14 resulted in half 
of the rsCD14 binding to LPS, when rLBP was present to 
facilitate binding  (Fig.  10,  lane  8).  This  suggests  a  low 
stoichiometry of binding of LPS to rsCD14, i.e., one or two 
LPS molecules per molecule of CD14. The stoichiometry of 
binding may also be estimated by observing the amount of 
rsCD14 needed to completely shift the mobility of a fixed 
dose of 3H-LPS.  17/~g/ml of rsCD14 (Mr =  50,000) bound 
nearly all  of a twofold excess of 3H-LPS (3  #g/ml; Mr = 
4,000) (Fig. 8, lane 7), suggesting again that one or two LPS 
molecules bind to CD14 to cause a  shift in mobility. 
CDI4-LPS Complexes Cause Activation of  PMN.  HUVEC 
are induced to synthesize E-selectin by mixtures of LPS and 
rsCD14 but not by either reagent alone (Fig. 2), suggesting 
that rsCD14 and LPS form complexes that activate cells. To 
explore this possibility, rsCD14 and LPS were incubated at 
37~  for various times,  and samples were tested for their 
ability to increase adhesion of PMN to fibrinogen (Fig.  11) 
and also examined by native PAGE for the extent of binding 
of LPS and rsCD14 (Fig.  11, inset). Our assay of PMN activa- 
tion permits kinetic analysis  since cells are exposed to LPS 
for only 20 min as opposed to the several hours used in assays 
of cytokine production or expression of surface molecules. 
We found that preincubation of rsCD14 with LPS was neces- 
sary to observe stimulation of PMN. Full activity in this assay 
required incubation of LPS with rsCD14 for at least 30 min 
before adding the samples to the PMN. The extent of  binding 
of LPS to rsCD14, seen as the proportion ofrsCD14 showing 
increased mobility in native PAGE,  followed a similar time 
course (Fig.  11, inset). LPS with rLBP also caused adhesion 
of PMN to fibrinogen-coated surfaces (Fig.  1), but no prein- 
cubation of LPS with rLBP was required to observe full ac- 
tivity (not shown). These experiments strongly suggest that 
rsCD14 and LPS must form complexes in order to activate 
Figure 10.  rLBP  acts at sub- 
stoichiometric  concentrations 
to accelerate  binding of LPS to 
rsCD14, rsCD14 (30/zg/ml)  was 
incubated with varying  doses of 
LPS (Re) with  (lanes 6-9) or 
without  (lanes I-5)  rLBP (1 
/xg/ml) for 30 minutes at 37~ 
run in a 4-20% native  polyacryl- 
amide gel, and the gel was stained 
with silver.  Lane  1, rsCD14 alone; 
lanes a, 0.15/~g/ml LPS; lanes b, 
0.5/zg/ml LPS; lanes  c, 1.5/xg/ml 
LPS; lanes d, 5 #g/ml LPS. 
Figure  11.  Preincubation  of LPS and rsCD14 is necessary  for activa- 
tion of integrins on PMN. rsCD14 (30/~g/ml) was incubated  with LPS 
(Re, 5 #g/ml) at 37~  for increasing times. A portion of each sample 
was diluted 1:10 in PBS and tested for its ability  to promote  adhesion to 
fibrinogen, as described  in Materials and Methods. As controls, rsCD14 
alone or LPS alone  was incubated  for 0 or 120 min at 37~  and assayed 
in the same way. Values  averaged  from  two experiments  are expressed  rela- 
tive to background  binding induced  by buffer  alone (=1). The remainder 
of each sample was run in an 8-16% native polyacrylamide  gel, and the 
gel was stained with silver (inset). Lane  I, CD14 alone; lanes 2-6, CD14 
+  LPS incubated for the indicated times. 
274  CD14  Binds Lipopolysaccharide cells, and show that rLBP and other serum proteins are not 
necessary for stimulating cells with rsCD14-LPS complexes. 
They also suggest that  the interaction  of LPS with LBP is 
much faster than the binding of LPS to CD14, which is con- 
sistent with the proposed role of LBP in facilitating the transfer 
of LPS to CD14. 
We wish to stress that rsCD14 enhances the adhesion of 
PMN to fibrinogen (Fig.  11) yet blocks the adhesion of mac- 
rophages to ELPS (Fig.  3) because these two adhesion assays 
measure entirely different adhesion events. Adhesion of ELPS 
to macrophages represents binding  of LPS on the erythro- 
cyte to membrane-bound CD14 on the macrophages,  and com- 
petition by rsCD14 is thus easy to envision.  On the other 
hand, the adhesion of PMN to fibrinogen represents binding 
of leukocyte integrins on the PMN to fibrinogen on plastic 
surfaces.  Since CD14 does not serve as a receptor or a ligand 
in this adhesion, rsCD14 should not block adhesion. Rather, 
our assay exploits the role of CD14 as an agonist;  rsCD14 
stimulates  the leukocyte to activate its integrins  and adhe- 
sion is the readout. 
Discussion 
Here we show that rLBP accelerates  the direct binding of 
LPS to rsCD14 and that LPS-rsCD14 complexes stimulate 
cells. These findings suggest a general mechanism for the in- 
teraction of LPB, LPS, and CD14 that is consistent with and 
explains a number of findings in the literature.  Some studies 
with CD14-bearing cells have shown an apparently absolute 
requirement for LBP or serum proteins in mediating CD14- 
dependent responses to LPS (4,  7), while others have  sug- 
gested that LPS alone, in the absence of serum opsonins, can 
stimulate cells in a CD14-dependent fashion (29-31). CD14- 
dependent stimulation of cells in the absence of LBP or serum 
was also seen in cells that lack cell surface CD14 (11), a finding 
confirmed here and in additional recent reports (14-16). Fi- 
nally,  Kitchens  et  al.  (31)  observed low  levels  of CD14- 
dependent binding of radiolabeled LPS to cells in the absence 
of LBP. Our observation that LBP facilitates binding of LPS 
to CD14 but is not absolutely required for binding offers an 
explanation for these findings.  Assays employing a very short 
incubation of cells  with  LPS,  such as the assay measuring 
adhesion of PMN to fibrinogen described here (20 min), may 
show a strong requirement for LBP while assays that require 
longer incubations,  such as induction of cytokine synthesis 
in macrophages, provide time for uncatalyzed binding of LPS 
to CD14. These assays show that LBP increases  the rate and 
sensitivity of the response (3).  The  above interpretation  is 
underscored by the finding that the strongly LBP-dependent 
activation of PMN (Fig.  1) can be made LBP-independent 
by preincubation  of LPS with rsCD14  (Fig.  11). 
The binding of LPS to CD14 is strongly enhanced by sub- 
stoichiometric concentrations of LBP. Fig. 10 shows that each 
molecule of LBP causes the movement of 10 molecules LPS 
into CD14. If the LBP, previously shown to have a binding 
site for a single LPS molecule (32),  were consumed upon 
transfer of that molecule of LPS, it could not perform mul- 
tiple rounds of this reaction.  Since we see multiple rounds 
of transfer,  the LBP must not be consumed.  This point is 
amplified in Fig. 9. In the first 10 min of the reaction, each 
molecule of LBP has transferred  at least 50 copies of LPS 
(about one third of the total) to CD14. If the LBP were con- 
sumed after these 50 cycles, the reaction would halt.  How- 
ever, it is clear from Fig. 9 that in the following 20 min the 
LBP continues to transfer LPS to CD14, not stopping until 
all of the LPS (a 150-fold molar excess over LBP) is trans- 
ferred.  Noncatalytic transfer of LPS to CD14 is negligible 
during this interval. While it is possible that a small fraction 
of the LBP is inactivated or lost upon each round of transfer, 
measurements of this loss would be difficult and would not 
materially alter the finding that LBP may transfer LPS to CD14 
without being consumed. We conclude from these findings 
that  LBP acts as a lipid transfer protein,  a view consistent 
with  the  structural  homology of LBP to cholesterol ester 
transfer protein (CETP) (3), a protein that redistributes cho- 
lesterol esters among lipoprotein particles.  We believe that 
binding of LBP to CD14 is necessary to achieve transfer of 
LPS to CD14. However, the interaction of LBP with CD14 
is likely to be short-lived, and we presume that this explains 
our inability to observe stable complexes of LBP and rsCD14 
in native PAGE. The interaction of LBP with CD14 might 
be more stable when surface-bound components, rather than 
soluble components, are used. Particles coated with LPS-LBP 
complexes bind to CD14 on macrophages (6), suggesting the 
formation of a relatively stable ternary complex. We have ob- 
served, however, that ELPS-LBP detach from macrophages 
upon incubation at 37~  (Wright,  S. D., unpublished ob- 
servation),  suggesting that  even the interaction  of surface- 
bound CD14 and LBP is transient.  The apparent  catalytic 
role of LBP suggests that its description as a "binding pro- 
tein" may be misleading and that to reflect its function faith- 
fully, assays of LBP should measure  a rate. 
We have demonstrated here that rsCD14 binds LPS directly, 
and that complexes of LPS and rsCD14 are biologically ac- 
tive. Stimulation of PMN by LPS was dramatically enhanced 
by rsCD14,  and the magnitude  of the response to LPS in- 
creased with the degree of binding of LPS to rsCD14 (Fig. 
11). These observations confirm the biological importance 
of the binding of LPS to CD14. They further suggest that 
the role of rLBP is limited to accelerating movement of LPS 
into CD14 and that it may not play a further role in interac- 
tions with  cells  and  signal transduction. 
Our  finding  of direct  stoichiometric binding  of LPS to 
CD14 confirms several suggestive findings in the literature. 
Tobias et al. observed that 12SI-ASD-LPS, a photoactivatable 
cross-linking  probe, could be cross-linked to mCD14  (33) 
and sCD14 (15), when added in the presence, but not in the 
absence, of LBP. These studies suggest a close association of 
LPS with CD14 in LPS-LBP-CD14 complexes, but do not 
establish  specific  binding  of LPS to  CD14.  Very recently, 
Haziot et al. (14) showed binding ofbiotinylated LPS to plastic 
plates that was increased significantly if the plates were first 
coated with recombinant  CD14,  a finding consistent with 
direct binding  of LPS to CD14.  Our results represent  the 
first direct evidence for stoichiometric binding of LPS to CD14 
275  Hailman  et al. using soluble components,  and the first study linking  this 
binding  with  functional  responses of cells. 
The binding of LPS to rsCD14 that we observed appears 
to be of high affinity inasmuch as complexes were stable during 
electrophoresis. The affinity of LBP for LPS has been reported 
as "010 -9 M  (32), and the affinity of rsCD14 for LPS must 
be greater than this,  since LBP facilitates  binding of CD14 
to LPS, rather than competing for binding to LPS.  Strong 
interaction  with a lipid such as LPS is consistent with  the 
primary structure of CD14, which exhibits 13 "leucine-rich" 
motifs. These repeat motifs have been proposed to bind lipids 
by forming  amphipathic  beta sheets  (34,  35). 
It should be noted that most of our studies used concen- 
trations  of LPS much  higher  than  the presumed binding 
affinity of CD14 and much higher than  the concentrations 
needed to stimulate cells. Our studies required high concen- 
trations  of LPS in order to equal the molar  concentration 
of rsCD14 needed for detection in our gel assays. However, 
high concentrations of LPS do not appear to be required for 
binding of LPS to rsCD14; the concentration of free, soluble 
LPS appears to be very low after incubation  with rsCD14 
(Fig. 8, lanes 7 and 8; Fig. 9, lanes 9-13). We are currently 
seeking methods  to accurately measure binding  of LPS to 
CD14 using lower concentrations  of these reagents. 
We observed a discrete enhancement of electrophoretic mo- 
bility of rsCD14 upon binding of LPS.  One explanation of 
this finding is that binding of each LPS molecule (Re, R595) 
only adds "03 kD of weight, a small increment in a protein 
of '050 kD, but adds at least four negative charges (36); com- 
plexes  of CD14  and  LPS  might  therefore  have  a  higher 
charge/mass  ratio than  monomers of CD14.  Alternatively, 
a conformational change in CD14 may occur upon binding 
LPS,  resulting  in  a more compact  tertiary  structure,  Our 
studies do not distinguish  between these two possibilities. 
The LPS-rsCD14 complexes formed with equimolar LPS 
and rsCD14  (Fig.  10,  lane 8) had the electrophoretic mo- 
bility of Form 2 (Fig. 4). However, there was a second dis- 
crete increase in the mobility of rsCD14, which required at 
least a 100-fold molar excess of LPS (Form 3, Fig. 4). Thus, 
rsCD14 may have an additional,  lower-affinity binding  site 
for LPS. Because the biological activity of rsCD14-LPS com- 
plexes correlated with a shift in mobility of rsCD14 to Form 
2 (Fig. 11), the second shift and the proposed second binding 
site may not be physiologically relevant. 
Smooth LPS, several forms of rough LPS, and the biosyn- 
thetic LPS precursor lipid IVa all competed for binding of 
3H-LPS  to  CD14,  suggesting  that  CD14  can  bind  many 
forms of LPS (Fig.  6).  The interaction  of CD14 with lipid 
IVa is consistent with the studies of Kitchens et al. (31), who 
observed that deacylated LPS, which, like lipid IVa lacks sec- 
ondary fatty adds, is bound by leukocytes in a CD14-dependent 
fashion. Whereas rough and smooth LPS strongly promote 
cellular responses, lipid IVa and deacylated LPS fail to stimu- 
late cells, acting instead as antagonists of LPS (37). Since lipid 
IVa is recognized by both LBP (33) and CD14 (Fig.  6), the 
discrimination between agonist and antagonist may occur in 
a step subsequent to binding CD14, as has been previously 
suggested (36). 
LPS-rsCD14 complexes induced expression of E-selectin 
on HUVEC, a cell type that does not express mCD14, and 
induced activation of leukocyte integrins on PMN, a cell type 
that does express functionally active mCD14. These data sug- 
gest that sCD14 may play an important role in the responses 
of all cells to LPS. The importance of sCD14 is further sup- 
ported by its abundance in serum: sCD14 represents at least 
99% of the total amount of CD14 in blood, the remaining 
1% being found on the surface of phagocytic cells. Since it 
is present in at least 1,000-fold molar excess of the maximal 
amount  of LPS present during  sepsis  (38),  we believe that 
sCD14 represents an enormous reservoir for binding LPS in 
the blood, and that partitioning  of LPS into this and other 
reservoirs may play a crucial role in modulating the host re- 
sponse to gram-negative  bacterial infection. 
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